Annie’s brings pizza to frozen food aisles nationwide
BERKELEY, Calif. — An organic food brand is bringing pizza to the table.
Annie’s announced that it has launched the new family-sized rising crust frozen pizza. Made with organic ingredients, the new item is available in uncured pepperoni, four cheese and BBQ recipe chicken varieties.
"More and more, parents want convenient comfort foods made with higher quality ingredients for their families," Annie’s chief mom officer Sarah Bird said. "Annie’s remains committed to answering that call. Frozen pizza is a mainstay in millions of homes across the country — and now, families can choose an option made with organic ingredients that features the delicious taste people have come to expect from Annie’s, in a size large enough to feed the whole family."
Annie’s rising crust frozen pizza will be available this fall at retailers nationwide, including Kroger, Safeway, Target and more, for a suggested retail price of $7.99.
Study: Vaccinations in alternate settings like pharmacy save significant employer healthcare dollars
LONDON — A study recently published in the Cost Effectiveness and Resource Allocation journal found that when more vaccinations are administered in an alternate setting, such as a pharmacy, employers realize a greater cost benefit.
According to the study, in a typical U.S. population, an influenza immunization program will be cost-beneficial for employers when more than 37% of individuals receive vaccines in nontraditional settings, such as pharmacies. In a scenario where 50% of persons are vaccinated in nontraditional settings, estimated net savings were $6 per vaccinated employee or dependent. And immunization programs limited to a pharmacy setting produce an estimated net savings or $31 per vaccinated member.
"Although annual influenza vaccination could decrease the significant economic and humanistic burden of influenza in the United States, immunization rates are below recommended levels, and concerns remain whether immunization programs can be cost beneficial," stated Ian Duncan, the study’s lead author. "Both universal and targeted vaccination programs can be cost beneficial. Proper planning with cost models can help employers and policy makers develop strategies to improve the impact of immunization programs."
ProPhase rejects Matrixx acquisition proposal
DOYLESTOWN, Pa. — ProPhase Labs on Monday announced that it rejected an unsolicited, nonbinding proposal from Matrixx Initiatives to acquire the company for $1.40 per share in cash, subject to further due diligence by Matrixx.
ProPhase stock was up 20 cents to $1.39 in mid-afternoon trading.
Matrixx is the owner of the Zicam brand of cold and allergy products and is a direct competitor to ProPhase’s Cold-Eeze Cold Remedy product line.
On Sept. 4, Matrixx purchased for $200,000 a three-year option to acquire almost 1.5 million of the company’s common stock for $1.40 per share from Guy Quigley, ProPhase’s former chairman and CEO when the company was still known as Quigley’s. Matrixx also acquired from Quigley a voting proxy to vote the shares subject to the option.
"It remains our view that by investing in our Cold-Eeze brand, we are building our distribution platform and pipeline, which has led to securing increased shelf space with our retailers for the upcoming cold season, and which has provided us with the opportunity to introduce new and improved products, including the national launch of Cold-Eeze Oral Spray and Cold-Eeze Daytime/Nighttime QuickMelts for the upcoming cold season," ProPhase chairman and CEO Ted Karkus said.